Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study ) (DART)

• ClinicalTrials.gov Identifier: NCT02244801
• Recruitment Status: Completed
• First Posted: September 19, 2014
• Last Update Posted: October 15, 2018
• Sponsor: University of California, San Francisco
• Collaborator: Seventh Framework Programme
• Information provided by (Responsible Party): Sang-Mo Kang, University of California, San Francisco

Study Description

Brief Summary:

This Phase I pilot study will evaluate the safety, and tolerability of darTreg infusion for adult, de novo, living donor renal transplant recipients.

Condition or disease	Intervention/treatment	Phase
Kidney Disease	Drug: darTreg infusion	Phase 1

Detailed Description:

A single-center, open-label, dose-escalation pilot trial of a single infusion of darTregs in two dosing cohorts. This study is an independent single-center clinical trial. However, the organizational and mechanistic infrastructure of the study will be provided by the ONE Study project, a European Union funded collaborative project, whose objective is to assess distinct purified hematopoietic immunoregulatory cells as clinical therapies in solid organ transplantation. This study is one of multiple clinical trials within the framework of The ONE Study project, based on the same general design.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 6 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation: A ONE Study Clinical Trial
• Actual Study Start Date: April 2015
• Actual Primary Completion Date: September 2017
• Actual Study Completion Date: August 28, 2018

Arms and Interventions

Arm	Intervention/treatment
Cohort 1; 3 subjects treated with a target dose of 300 million darTreg with the possibility of expanding to 5 patients if safety signals should require additional patients be observed at the 300 million dose. The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients.	Drug: darTreg infusion; The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete. Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects.; Other Name: darTregs
Cohort 2; The second cohort will comprise a minimum of 3 and up to 5 subjects treated at a target dose of 900 million darTreg, depending on how many patients were required to be treated in lower dose group. The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients.	Drug: darTreg infusion; The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete. Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects.; Other Name: darTregs

Outcome Measures

Primary Outcome Measures :

1. Incidence of biopsy-confirmed acute rejection (BCAR) following renal transplantation. [ Time Frame: 60 weeks post renal transplantation ]
   Explore the immunomodulatory potential, safety and tolerability of a single infusion of darTregs as adjunct immunosuppressive treatment through the incidence of biopsy-confirmed acute rejection (BCAR) within 60 weeks following renal transplantation.

Secondary Outcome Measures :

1. Time to first acute rejection episode [ Time Frame: 60 weeks post renal transplantation ]
2. Severity of acute rejection episodes [ Time Frame: 60 weeks post renal transplantation ]
   severity of acute rejection episodes based on response to treatment and histological scoring
3. Total immunosuppressive burden at 60 weeks post-transplantation [ Time Frame: 60 weeks post renal transplantation ]
   Total immunosuppressive burden assessed at last study visit
4. Prevention of chronic graft dysfunction (chronic rejection or IF/TA) [ Time Frame: 60 weeks post renal transplantation ]
   chronic graft dysfunction assessed by clinical (impairment of GFR) and histopathological (Banff staging) measures
5. Incidence of post-transplant dialysis, inclusion on the transplant waiting list or re-transplantation following graft loss through rejection [ Time Frame: 60 weeks post renal transplantation ]
6. Avoidance of drug-related complications by immunosuppressant reduction [ Time Frame: 60 weeks post renal transplantation ]
   Assessed by the incidence of reported adverse drug reactions
7. Biochemical disturbances caused by cell infusion [ Time Frame: 1 week ]
   Assessed by Incidence of acute toxicities associated with infusion of the cell product
8. Over-suppression of the immune system assessed by the incidence of major and/or opportunistic infections especially CMV (cytomegalovirus ), EBV (Epstein-Barr virus) and polyoma virus [ Time Frame: 60 weeks post renal transplantation ]
9. Incidence of neoplasia [ Time Frame: 60 weeks post renal transplantation ]
10. Incidence of patients treated for subclinical acute rejection [ Time Frame: 60 weeks post transplantation ]

Other Outcome Measures:

1. Incidence of malignancies arising directly from darTreg infusion [ Time Frame: 60 weeks ]
2. incidence of autoimmune disorders [ Time Frame: 60 weeks post transplantation ]
3. A Health-Economics Subproject will evaluate the health-related qualify-of-life of trail patients using patient-reported outcome measures [ Time Frame: 60 weeks post transplantation ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria: (organ donor eligibility)

1. Eligible for live kidney donation
2. At least 18 years of age
3. An ABO blood type compatible with the organ recipient
4. Willing and able to provide a blood sample for The ONE Study IM (Immune Monitoring) Subproject
5. Willing to provide personal and medical/biological data for the trial analysis
6. Eligible to give blood for B cell source prior to organ donation
7. Signed and dated written informed consent*. *For subjects unable to read and/or write, oral informed consent observed by an independent witness is acceptable if the subject has fully understood oral information given by the Investigator. The witness should sign the consent form on behalf of the subject.

In signing the donor information sheet/informed consent form (DIS/ICF), organ donors agree to undergo phlebotomy to provide donor B cells for the production of darTreg, to provide a blood sample for the IM Subproject, and permit access to their medical records for the collection of specified demographic and medical/biological data for the trial.

Organ Recipient eligibility:

A prospective kidney transplant recipient is eligible for enrollment into the study if all of the following inclusion criteria apply:

1. Chronic renal insufficiency necessitating kidney transplantation and approved to receive a primary kidney allograft from a living donor
2. At least 18 years of age
3. Able to commence the immunosuppressive regimen at the protocol-specified time point
4. Willing and able to participate in The ONE Study IM and HEC (Health-Economics Subproject) subprojects
5. Adequate venous access to support leukapheresis

6. Signed and dated written informed consent*.

   • For patients unable to read and/or write, oral informed consent observed by an independent witness is acceptable if the patient has fully understood oral information given by the Investigator. The witness should sign the consent form on behalf of the patient.

Exclusion Criteria: (organ donor)

If a prospective donor fulfills any of the following criteria, they are ineligible for the trial:

1. Genetically identical to the prospective organ recipient at the HLA (human leukocyte antigen) loci (0-0-0 mismatch)
2. CMV-positive and donating to a CMV-negative recipient
3. Exposure to any investigational agents at the time of kidney donation, or within 28 days prior to kidney donation
4. Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel
5. Subjects unable to freely give their informed consent (e.g. individuals under legal guardianship).

Exclusion criteria (organ recipient)

1. Patient has previously received any tissue or organ transplant other than the planned kidney graft
2. Known contraindication to the protocol-specified treatments / medications
3. Genetically identical to the prospective organ donor at the HLA (human leukocyte antigen) loci (0-0-0 mismatch)
4. PRA (panel reactive antibody) grade > 40% within 6 months prior to enrollment
5. Previous treatment with any desensitization procedure (with or without IVIg)
6. Concomitant malignancy or history of malignancy within 5 years prior to planned study entry (excluding successfully-treated non-metastatic basal/squamous cell carcinoma of the skin)
7. Evidence of significant local or systemic infection
8. HIV-positive, EBV-negative or suffering chronic viral hepatitis
9. CMV-negative and receiving a kidney from a CMV-positive donor
10. Significant liver disease, defined as persistently elevated AST (aspartate aminotransferase) and/or ALT(alanine aminotransferase) levels > 2 x ULN (Upper Limit of Normal range)
11. Malignant or pre-malignant hematological conditions
12. Neutrophils < 1000/μl ; platelets < 100,000/μl
13. Regulatory T cells present in peripheral blood at <30/µL
14. Any uncontrolled medical condition or concurrent disease that could interfere with the study objectives
15. Any condition which, in the judgment of the Investigator, would place the subject at undue risk
16. Ongoing treatment with systemic immunosuppressive drugs at study entry
17. Patients who have received anti-T cell therapy within 30 days prior to transplant surgery
18. Participation in another clinical trial during the study or within 28 days prior to planned study entry
19. Female patients of reproductive potential with a positive pregnancy test at enrollment
20. Female patients who are breast-feeding
21. All female patients of reproductive potential* UNLESS the patient is willing to use an acceptable birth control for the duration of the study unless the patient chooses abstinence (she chooses to avoid heterosexual intercourse completely) (See Table 2. Acceptable Contraception Methods for Females of Reproductive Potential)
22. Male patients unwilling to use a reliable and effective form of contraception for 3 months after darTreg dosing
23. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up visit schedule
24. Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel

25. Patients unable to freely give their informed consent (e.g. individuals under legal guardianship).

    • Females of reproductive potential include girls who have entered puberty and all women who have a uterus and have not passed through menopause. Menopause is the permanent end of menstruation and fertility. Menopause should be clinically confirmed by a patient's healthcare practitioner. Some commonly used diagnostic criteria include 1) 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or 2) postsurgical from a bilateral oophorectomy.

Exclusion Criteria B (organ recipient)

Below are exclusion criteria to be assessed post-transplantation and prior to darTreg infusion. Subjects who meet any of these criteria should not receive a darTreg-infusion:

1. Unacceptable darTreg product.
2. Delayed graft function (requiring dialysis post-transplant).
3. Requiring oxygen supplementation to keep capillary oxygen saturations >95%.
4. Any medical or technical complications (e.g. myocardial infarction, urine leak, wound dehiscence, pneumonia, ongoing fevers, etc.) that in the judgment of the investigators or responsible clinician would put the subject at undue risk.-

Contacts and Locations

Locations

United States, California

University of California San Francisco - Transplant Department. 513 Parnassus Ave HSE 504

San Francisco, California, United States, 94143

Sponsors and Collaborators

University of California, San Francisco

Seventh Framework Programme

Investigators

• Principal Investigator: Sang-Mo Kang, M.D.; University of California, San Francisco

More Information

Publications of Results:

MERRILL JP, MURRAY JE, HARRISON JH, GUILD WR. Successful homotransplantation of the human kidney between identical twins. J Am Med Assoc. 1956 Jan 28;160(4):277-82. doi: 10.1001/jama.1956.02960390027008. No abstract available.

Other Publications:

ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med. 1999 Aug 15;18(15):1905-42. No abstract available.

Francillon A, Pickering G, Belorgey C. Exploratory clinical trials: implementation modes & guidelines, scope and regulatory framework. Therapie. 2009 May-Jun;64(3):149-59. doi: 10.2515/therapie/2009022. Epub 2009 Aug 13. English, French.

Morris PJ. Transplantation--a medical miracle of the 20th century. N Engl J Med. 2004 Dec 23;351(26):2678-80. doi: 10.1056/NEJMp048256. No abstract available.

Sayegh MH, Carpenter CB. Transplantation 50 years later--progress, challenges, and promises. N Engl J Med. 2004 Dec 23;351(26):2761-6. doi: 10.1056/NEJMon043418. No abstract available.

Gibson T, Medawar PB. The fate of skin homografts in man. J Anat. 1943 Jul;77(Pt 4):299-310.4. No abstract available.

Medawar PB. The behaviour and fate of skin autografts and skin homografts in rabbits: A report to the War Wounds Committee of the Medical Research Council. J Anat. 1944 Oct;78(Pt 5):176-99. No abstract available.

Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004 Dec 23;351(26):2715-29. doi: 10.1056/NEJMra033540. No abstract available. Erratum In: N Engl J Med. 2005 Mar 10;352(10):1056.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS, Tang Q, Guinan EC, Battaglia M, Burlingham WJ, Roberts ISD, Streitz M, Josien R, Boger CA, Scotta C, Markmann JF, Hester JL, Juerchott K, Braudeau C, James B, Contreras-Ruiz L, van der Net JB, Bergler T, Caldara R, Petchey W, Edinger M, Dupas N, Kapinsky M, Mutzbauer I, Otto NM, Ollinger R, Hernandez-Fuentes MP, Issa F, Ahrens N, Meyenberg C, Karitzky S, Kunzendorf U, Knechtle SJ, Grinyo J, Morris PJ, Brent L, Bushell A, Turka LA, Bluestone JA, Lechler RI, Schlitt HJ, Cuturi MC, Schlickeiser S, Friend PJ, Miloud T, Scheffold A, Secchi A, Crisalli K, Kang SM, Hilton R, Banas B, Blancho G, Volk HD, Lombardi G, Wood KJ, Geissler EK. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. 2020 May 23;395(10237):1627-1639. doi: 10.1016/S0140-6736(20)30167-7. Erratum In: Lancet. 2020 Jun 27;395(10242):1972.

• Responsible Party: Sang-Mo Kang, Associate Professor of Surgery, University of California, San Francisco
• ClinicalTrials.gov Identifier: NCT02244801
• Other Study ID Numbers: ONEdarTreg14
• First Posted: September 19, 2014
• Last Update Posted: October 15, 2018
• Last Verified: October 2018

Additional relevant MeSH terms:

Kidney Diseases; Urologic Diseases